Outcomes Studies

Lung Quality Improvement (Non-Small Cell Lung Cancer), 2018

  • Surgery is not the first course of treatment for cN2 M0 lung cases (LNoSurg)
  • Standard: 85%
  • 100% concordance with this measure

Breast Accountability Measures, 2018

  • Tamoxifen or third generation aromatase inhibitor is recommended or administered within one year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB-III hormone receptor positive breast cancer (HT)
  • Standard: 90%
  • 93% concordance

Colon Quality Improvement Measure, 2018

  • At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (12 RLN)
  • Standard: 85%
  • 100% concordance

Gastric Quality Improvement, 2018

  • At least 15 regional lymph nodes and removed and pathologically examined for resected gastric cancer (G15RLN)
  • Standard 80%
  • 100% concordance

Lung Quality Improvement, 2017

  • Surgery is not the first course of treatment for cN2 M0 lung cases
  • Standard 85%
  • 100% concordance with this measure

Colon Accountability Measure, 2017

  • Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer (ACT)
  • Standard- not determined
  • 100% concordance with this measure

Breast Accountability Measures, 2016

  • Radiation Therapy is administered within one year of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer (BCSRT)
  • Standard : 90%
  • 100% concordance with this measure
  • Tamoxifen or third generation aromatase inhibitor is considered or administered within 365 days of diagnosis for women with AJCC T1cN0M0 or Stage II or III hormone receptor positive breast cancer (HT)
  • Standard : 90%
  • Concordance: 97%